The document outlines SQM, a global mining company based in Chile, and discusses its business lines including being a leading producer of potassium nitrate, iodine, lithium, and industrial chemicals. It highlights SQM's unique natural resources in Chile, sales to over 115 countries, solid financial position, and capital expenditure plans to increase production capacities of various products.
The document provides an overview of SQM, a global specialty plant nutrients and lithium company. It discusses SQM's business segments, financial profile, investment highlights, and capital expenditure program. Key points include that SQM has world-leading market shares in iodine, lithium, and potassium nitrate, with sales in over 115 countries. It also has a solid financial position and experienced management team. Recent capital expenditures have focused on expanding production capacities for various products.
SQM is a global company that produces specialty plant nutrients, iodine, lithium, potassium nitrate, and industrial chemicals. It has unique and abundant natural resources located in Chile. SQM has invested $2 billion over the past 5 years to expand production capacity. It is the leading global producer of potassium nitrate and iodine, and the lowest cost producer of lithium. SQM has a solid financial position with low debt levels and high liquidity. It expects capital expenditures to decrease in 2014 after significant investments to boost production capacity.
SQM is a global producer of specialty plant nutrients, lithium, iodine, and industrial chemicals. It has unique and abundant natural resources in Chile that allow it to be the lowest cost producer. It has a solid financial position and sells its diverse product portfolio globally in over 115 countries. While forward-looking statements involve risks and uncertainties, SQM is well positioned due to its leading market positions, low production costs from its natural resources, and experienced management team.
The document discusses SQM, a global company based in Chile that produces specialty plant nutrients, iodine, lithium, potassium chloride, and industrial chemicals. It notes that any statements about future economic performance or other forward-looking statements involve risks and uncertainties. It also states that risks that could affect the accuracy of forward-looking statements are identified in public filings with the SEC. The agenda then outlines SQM's business lines and investment highlights, including its unique natural resources, global sales, market leading positions, and competitive advantages.
This document provides an overview of SQM, a global producer of specialty plant nutrients, iodine, lithium, potassium, and industrial chemicals. It discusses SQM's leading market positions, diverse product offerings sold globally, abundant natural resources in Chile, and recent financial performance. Risk factors and opportunities are also reviewed, including investments in expanding production capacity and metallic mineral exploration.
This document contains forward-looking statements regarding SQM's business outlook, future economic performance, and financial projections. These statements are estimates based on currently available information and involve risks and uncertainties that could cause actual results to differ materially. Risks that could affect the accuracy of the forward-looking statements are identified in public filings with the SEC. Forward-looking statements should be considered in light of the risk factors identified in those filings.
The document contains forward-looking statements about the company's business outlook, future economic performance, and financial projections. These statements are estimates based on currently available information and involve risks and uncertainties that could cause actual results to differ materially. Risks that could affect the accuracy of the forward-looking statements are identified in public filings with the SEC. Forward-looking statements should be considered in light of these risk factors.
SQM is a global producer of specialty plant nutrients, industrial chemicals, and lithium. It has unique and abundant natural resources in Chile. The presentation highlights SQM's leading market positions, solid financial performance, and opportunities for future growth through increased sales volumes and cost reductions. Key investment highlights include low-cost operations, sales diversification globally, and a strong financial position.
The document provides an overview of SQM, a global specialty plant nutrients and lithium company. It discusses SQM's business segments, financial profile, investment highlights, and capital expenditure program. Key points include that SQM has world-leading market shares in iodine, lithium, and potassium nitrate, with sales in over 115 countries. It also has a solid financial position and experienced management team. Recent capital expenditures have focused on expanding production capacities for various products.
SQM is a global company that produces specialty plant nutrients, iodine, lithium, potassium nitrate, and industrial chemicals. It has unique and abundant natural resources located in Chile. SQM has invested $2 billion over the past 5 years to expand production capacity. It is the leading global producer of potassium nitrate and iodine, and the lowest cost producer of lithium. SQM has a solid financial position with low debt levels and high liquidity. It expects capital expenditures to decrease in 2014 after significant investments to boost production capacity.
SQM is a global producer of specialty plant nutrients, lithium, iodine, and industrial chemicals. It has unique and abundant natural resources in Chile that allow it to be the lowest cost producer. It has a solid financial position and sells its diverse product portfolio globally in over 115 countries. While forward-looking statements involve risks and uncertainties, SQM is well positioned due to its leading market positions, low production costs from its natural resources, and experienced management team.
The document discusses SQM, a global company based in Chile that produces specialty plant nutrients, iodine, lithium, potassium chloride, and industrial chemicals. It notes that any statements about future economic performance or other forward-looking statements involve risks and uncertainties. It also states that risks that could affect the accuracy of forward-looking statements are identified in public filings with the SEC. The agenda then outlines SQM's business lines and investment highlights, including its unique natural resources, global sales, market leading positions, and competitive advantages.
This document provides an overview of SQM, a global producer of specialty plant nutrients, iodine, lithium, potassium, and industrial chemicals. It discusses SQM's leading market positions, diverse product offerings sold globally, abundant natural resources in Chile, and recent financial performance. Risk factors and opportunities are also reviewed, including investments in expanding production capacity and metallic mineral exploration.
This document contains forward-looking statements regarding SQM's business outlook, future economic performance, and financial projections. These statements are estimates based on currently available information and involve risks and uncertainties that could cause actual results to differ materially. Risks that could affect the accuracy of the forward-looking statements are identified in public filings with the SEC. Forward-looking statements should be considered in light of the risk factors identified in those filings.
The document contains forward-looking statements about the company's business outlook, future economic performance, and financial projections. These statements are estimates based on currently available information and involve risks and uncertainties that could cause actual results to differ materially. Risks that could affect the accuracy of the forward-looking statements are identified in public filings with the SEC. Forward-looking statements should be considered in light of these risk factors.
SQM is a global producer of specialty plant nutrients, industrial chemicals, and lithium. It has unique and abundant natural resources in Chile. The presentation highlights SQM's leading market positions, solid financial performance, and opportunities for future growth through increased sales volumes and cost reductions. Key investment highlights include low-cost operations, sales diversification globally, and a strong financial position.
This document provides an overview, agenda, and financial information for SQM's specialty business presentation in May 2013. The summary highlights that SQM is a world leader in specialty chemicals like lithium, iodine, and potassium nitrate. It also notes SQM has a strong financial profile with 46% EBITDA margins and revenue growth of over 69% since 2009. The document outlines SQM's growth opportunities across its fertilizer and specialty chemical segments.
SQM presented its business outlook, highlighting its position as a world leader in specialty chemicals. It discussed its unique natural resources in Chile and operational synergies that give it a low-cost structure. SQM expects continued growth across its specialty plant nutrition, iodine, lithium and solar salts businesses. It outlined a $500 million capital expenditure plan for 2013 focused on expanding potassium-based products and increasing production capacities. Financially, SQM has a strong profile with rising revenues and net income in recent years and stable EBITDA margins above 45%.
Merck announced strong financial results for the first quarter of 2006, with earnings per share of $0.78 excluding restructuring charges. Solid performance of key drugs like ZOCOR, SINGULAIR and vaccines, along with partnerships, drove earnings. Merck raised full-year 2006 guidance, now anticipating EPS between $2.32-$2.40 excluding charges. Performance of major franchises like SINGULAIR, COZAAR/HYZAAR and FOSAMAX was mixed, with US sales remaining strong but international sales declining due to generics.
Canadian Institute Conference - Arvind Mani's Presentation - Final - April 1 ...Arvind Mani
This document summarizes global trends in drug pricing, reimbursement, and market access. It provides data on pharmaceutical R&D spending, employment, sales, and other metrics for key global markets including the US, Europe, and Canada. It then discusses factors that impact drug pricing internationally and in Canada, such as external price referencing and currency fluctuations. Emerging trends in global cost containment like delisting treatments, off-label prescribing, and biosimilar uptake that could affect the Canadian market are also examined based on a survey of international and Canadian industry and payer perspectives.
The global market for rheology modifiers is expected to grow from $ 5,504.0 million in 2021 to $ 6,965.3 million in 2027. The market is expected to grow at a CAGR of 3.4% over the forecast period (2021-2027). Some of the market's key participants are Air Products And Chemicals, Inc., Akzo Nobel N.V., Arkema, Ashland Inc., BYK Additives & Instruments, Basf Se, Croda International Plc, DowDuPont, Elementis Plc, Evonik, Huaxia Chemicals, Kito, Kusumoto, Lubrizol Corporation, Qinghong, San Nopco Ltd, Wanhua. This report intends to identify significant growth areas and to explore relevant market strategies. This in-depth analysis delves into the global market for rheology modifiers. The primary goal of this research is to examine the potential growth areas, significant trends, and the market's impact on the industry. The report also reviews the adoption of rheology modifiers in both established and emerging markets.
This document outlines Sanofi's strategic roadmap for 2015-2020. It discusses Sanofi's vision of being a focused global healthcare company in pharmaceuticals, vaccines, and consumer healthcare. The roadmap identifies four strategic priorities: 1) reshaping the portfolio, 2) delivering outstanding launches, 3) simplifying the organization, and 4) sustaining innovation in R&D. Specific goals and initiatives are outlined for each of Sanofi's global business units.
David Meeker, M.D. provided an overview of Sanofi Genzyme's key accomplishments and strategy. Some highlights include:
- Three major product launches and three regulatory submissions since April 2015.
- Strategic R&D alliances formed in oncology and diabetes.
- Announced a transaction to reshape the portfolio by focusing on specialty care and consumer healthcare.
- Rare diseases franchise grew 11% in 2015 through new patient identification efforts.
- Multiple sclerosis franchise sales doubled to over €1 billion led by Aubagio and Lemtrada.
- RNAi programs for ATTR amyloidosis and hemophilia B showed promising phase 2 results.
- Strategy to grow immunology by developing
Market research report on Feed Nucleotides gives an insight into global Feed Nucleotides value and volume market. The report also provides market analytics by application, and by source. The market is divided by Application into Immune Stimulators, Dietary Supplements and Other; by Source into Yeast/Yeast Extracts, Single Celled Organisms and Other; and by Animal Categories into Swine, Poultry, Aquaculture and Other. The market is also divided by Type into IMP (Inosine Monophosphate), GMP (Guanosine Monophosphate) and Other (AMP+CMP+UMP). The study also provides global market analysis for Feed Additives and Nucleotides, both in value and volume terms. Compilation of Worldwide Patents and Research related to Feed Nucleotides is also provided. Projections and estimates are also illustrated by geographic regions encompassing the North America, Europe, Asia-Pacific, and Rest of World with 148 exclusive graphically represented exhibits.
Merck announced strong financial results for the second quarter of 2006, with earnings per share of $0.73 excluding restructuring charges. Revenue increased 6% to $5.8 billion driven by strong sales of drugs like ZOCOR, SINGULAIR, and vaccines. Merck also gained FDA approval for new vaccines GARDASIL and ZOSTAVAX, and raised full-year 2006 guidance. In addition, the company reported progress on drugs in development like JANUVIA and ZOLINZA.
Jp morgan 2016 healthcare conference finalInvestorBruker
The document is Bruker Corporation's presentation for investors. It summarizes that Bruker drives profitable growth through enabling scientific discoveries that improve life. It focuses on four strategic growth areas: life science research, applied markets/pharma, nano-analysis/materials research, and clinical/diagnostic markets. Bruker has transitioned from a transformation phase to focusing on operational excellence through initiatives like outsourcing and improving efficiency. Despite currency headwinds, Bruker has improved profitability and free cash flow in recent years.
The document summarizes Olivier Brandicourt's presentation at the JP Morgan Healthcare Conference on January 12, 2016. Some key points from the presentation include:
- Sanofi outlined four strategic priorities to drive future success - reshaping the portfolio, delivering outstanding launches, simplifying the organization, and sustaining innovation in R&D.
- Sanofi entered exclusive negotiations with Boehringer Ingelheim for a potential business swap that would make Sanofi a global leader in consumer healthcare and Boehringer Ingelheim the second largest animal health company.
- Sanofi highlighted plans to focus resources on key therapeutic areas and launch several major new products, with an expectation of €12-
The biotechnology industry had an unprecedented year in 2014, reaching new highs in revenues, R&D spending, profits, financing amounts, and market capitalization. Strong product sales and approvals helped boost investor sentiment and company valuations. A surge in IPOs and follow-on financings provided the industry with historic levels of capital to fund innovation.
BMO Capital Markets 25th Global Metals & Mining Conference PresentationKinrossGold
Kinross Gold Corporation presented at the BMO Capital Markets Global Metals & Mining Conference on February 28 - March 2, 2016. Kinross delivered strong operational performance in 2015, meeting or exceeding its revised guidance targets. Kinross expects to produce 2.7-2.9 million ounces of gold equivalent in 2016 at an all-in sustaining cost of $890-990 per ounce and capital expenditures of $595 million. Kinross' diversified portfolio is expected to source over 60% of 2016 production from its Americas mines. Kinross outlined organic growth opportunities from its La Coipa project in Chile and exploration programs at Bald Mountain and across its global portfolio.
This document summarizes Kinross Gold Corporation's presentation at the CIBC Whistler Institutional Investor Conference in January 2016. Key points include: Kinross is focused on operational excellence, quality over quantity, disciplined capital allocation, and maintaining a strong balance sheet. For 2015, Kinross expects gold equivalent production of 2.5-2.6 million ounces at a production cost of sales of $690-730 per ounce and all-in sustaining costs of $975-1,025 per ounce, and capital expenditures of $650 million. Over 50% of Kinross' estimated 2015 production is from mines in the Americas.
Kinross Gold Corporation held a Q1 2016 results conference call and webcast on May 11, 2016. Key highlights from the call include: Kinross delivered strong performance in Q1 2016 with production increasing and costs decreasing year-over-year. Kinross is on track to meet its 2016 guidance targets. The Tasiast Phase One project is progressing well with engineering 55% complete and major earthworks scheduled to begin in June. Phase One is expected to significantly increase production and reduce costs at Tasiast.
Kinross Gold Corporation presented at the TD Securities 2016 Mining Conference in January 2016. The presentation focused on Kinross' principles of operational excellence, quality over quantity, disciplined capital allocation, and maintaining a strong balance sheet. It provided updates on Kinross' diversified portfolio of operating mines and organic growth opportunities, including positive pre-feasibility study results for the La Coipa Project and concepts for a phased expansion at Tasiast.
Kinross Gold Corporation completed studies on a two-phased expansion of its Tasiast mine in Mauritania. Phase One involves expanding the processing capacity to 12,000 tonnes per day at an initial capital cost of $300 million, which is expected to increase average annual production to 409,000 ounces, reduce costs per ounce by 50%, and generate an after-tax IRR of 20%. Phase Two pre-feasibility studies were also completed. The two-phased approach offers significant growth potential at a lower cost than previously estimated and allows flexibility to potentially proceed with a larger expansion in the future. Kinross is proceeding with Phase One of the expansion.
Kinross Gold Corp European Gold Forum PresentationKinrossGold
Kinross Gold Corporation is a gold mining company that produced 2.6 million ounces of gold equivalent in 2015, meeting or exceeding its revised guidance targets. For 2016, Kinross expects production of 2.7-2.9 million ounces at a cost of sales of $675-735 per ounce and all-in sustaining costs of $890-990 per ounce. Capital expenditures are forecasted to be $755 million. The Americas are expected to contribute 61% of 2016 production at a cost of sales of $730-790 per ounce from its six mines in the US, Brazil and Chile. Kinross has a diversified portfolio of operating mines and development projects globally.
Kinross Gold Corporation reported its fourth quarter and full-year 2015 results. Key highlights included meeting or exceeding its revised 2015 guidance by producing 2.6 million ounces of gold equivalent at a cost of sales of $696 per ounce and capital expenditures of $610 million. The company also acquired two producing mines in Nevada, enhancing its American portfolio. For 2016, Kinross expects to produce between 2.7-2.9 million ounces of gold equivalent at a reduced overhead expense of $165 million and capital expenditures of $595 million, excluding potential expansion at Tasiast.
062916 nevada mine tour presentation final printedKinrossGold
Kinross Gold Corporation hosted a mine tour at its Bald Mountain Mine in Nevada on June 29-30, 2016. The presentation provided an overview of Bald Mountain, including:
1) Bald Mountain is a large, open-pit heap leach gold mine in Nevada with significant mineral reserves and upside potential from resource conversion and exploration.
2) Near-term opportunities exist to potentially double mineral reserve estimates by the end of Q1 2017 through conversion of the Vantage Complex and Saga Extension.
3) Longer-term opportunities for further mine life extension include converting measured and indicated resources to reserves with additional drilling and permitting. Bald Mountain also has extensive exploration potential across its large land package.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos Corporation will be releasing an investor presentation for the third quarter of 2016. The presentation will provide investors with information on the company's financial performance and business operations for the recent quarterly period. Details on Glaukos' progress, strategies, and outlook will be shared in the upcoming Q3 2016 investor presentation.
This document provides an overview, agenda, and financial information for SQM's specialty business presentation in May 2013. The summary highlights that SQM is a world leader in specialty chemicals like lithium, iodine, and potassium nitrate. It also notes SQM has a strong financial profile with 46% EBITDA margins and revenue growth of over 69% since 2009. The document outlines SQM's growth opportunities across its fertilizer and specialty chemical segments.
SQM presented its business outlook, highlighting its position as a world leader in specialty chemicals. It discussed its unique natural resources in Chile and operational synergies that give it a low-cost structure. SQM expects continued growth across its specialty plant nutrition, iodine, lithium and solar salts businesses. It outlined a $500 million capital expenditure plan for 2013 focused on expanding potassium-based products and increasing production capacities. Financially, SQM has a strong profile with rising revenues and net income in recent years and stable EBITDA margins above 45%.
Merck announced strong financial results for the first quarter of 2006, with earnings per share of $0.78 excluding restructuring charges. Solid performance of key drugs like ZOCOR, SINGULAIR and vaccines, along with partnerships, drove earnings. Merck raised full-year 2006 guidance, now anticipating EPS between $2.32-$2.40 excluding charges. Performance of major franchises like SINGULAIR, COZAAR/HYZAAR and FOSAMAX was mixed, with US sales remaining strong but international sales declining due to generics.
Canadian Institute Conference - Arvind Mani's Presentation - Final - April 1 ...Arvind Mani
This document summarizes global trends in drug pricing, reimbursement, and market access. It provides data on pharmaceutical R&D spending, employment, sales, and other metrics for key global markets including the US, Europe, and Canada. It then discusses factors that impact drug pricing internationally and in Canada, such as external price referencing and currency fluctuations. Emerging trends in global cost containment like delisting treatments, off-label prescribing, and biosimilar uptake that could affect the Canadian market are also examined based on a survey of international and Canadian industry and payer perspectives.
The global market for rheology modifiers is expected to grow from $ 5,504.0 million in 2021 to $ 6,965.3 million in 2027. The market is expected to grow at a CAGR of 3.4% over the forecast period (2021-2027). Some of the market's key participants are Air Products And Chemicals, Inc., Akzo Nobel N.V., Arkema, Ashland Inc., BYK Additives & Instruments, Basf Se, Croda International Plc, DowDuPont, Elementis Plc, Evonik, Huaxia Chemicals, Kito, Kusumoto, Lubrizol Corporation, Qinghong, San Nopco Ltd, Wanhua. This report intends to identify significant growth areas and to explore relevant market strategies. This in-depth analysis delves into the global market for rheology modifiers. The primary goal of this research is to examine the potential growth areas, significant trends, and the market's impact on the industry. The report also reviews the adoption of rheology modifiers in both established and emerging markets.
This document outlines Sanofi's strategic roadmap for 2015-2020. It discusses Sanofi's vision of being a focused global healthcare company in pharmaceuticals, vaccines, and consumer healthcare. The roadmap identifies four strategic priorities: 1) reshaping the portfolio, 2) delivering outstanding launches, 3) simplifying the organization, and 4) sustaining innovation in R&D. Specific goals and initiatives are outlined for each of Sanofi's global business units.
David Meeker, M.D. provided an overview of Sanofi Genzyme's key accomplishments and strategy. Some highlights include:
- Three major product launches and three regulatory submissions since April 2015.
- Strategic R&D alliances formed in oncology and diabetes.
- Announced a transaction to reshape the portfolio by focusing on specialty care and consumer healthcare.
- Rare diseases franchise grew 11% in 2015 through new patient identification efforts.
- Multiple sclerosis franchise sales doubled to over €1 billion led by Aubagio and Lemtrada.
- RNAi programs for ATTR amyloidosis and hemophilia B showed promising phase 2 results.
- Strategy to grow immunology by developing
Market research report on Feed Nucleotides gives an insight into global Feed Nucleotides value and volume market. The report also provides market analytics by application, and by source. The market is divided by Application into Immune Stimulators, Dietary Supplements and Other; by Source into Yeast/Yeast Extracts, Single Celled Organisms and Other; and by Animal Categories into Swine, Poultry, Aquaculture and Other. The market is also divided by Type into IMP (Inosine Monophosphate), GMP (Guanosine Monophosphate) and Other (AMP+CMP+UMP). The study also provides global market analysis for Feed Additives and Nucleotides, both in value and volume terms. Compilation of Worldwide Patents and Research related to Feed Nucleotides is also provided. Projections and estimates are also illustrated by geographic regions encompassing the North America, Europe, Asia-Pacific, and Rest of World with 148 exclusive graphically represented exhibits.
Merck announced strong financial results for the second quarter of 2006, with earnings per share of $0.73 excluding restructuring charges. Revenue increased 6% to $5.8 billion driven by strong sales of drugs like ZOCOR, SINGULAIR, and vaccines. Merck also gained FDA approval for new vaccines GARDASIL and ZOSTAVAX, and raised full-year 2006 guidance. In addition, the company reported progress on drugs in development like JANUVIA and ZOLINZA.
Jp morgan 2016 healthcare conference finalInvestorBruker
The document is Bruker Corporation's presentation for investors. It summarizes that Bruker drives profitable growth through enabling scientific discoveries that improve life. It focuses on four strategic growth areas: life science research, applied markets/pharma, nano-analysis/materials research, and clinical/diagnostic markets. Bruker has transitioned from a transformation phase to focusing on operational excellence through initiatives like outsourcing and improving efficiency. Despite currency headwinds, Bruker has improved profitability and free cash flow in recent years.
The document summarizes Olivier Brandicourt's presentation at the JP Morgan Healthcare Conference on January 12, 2016. Some key points from the presentation include:
- Sanofi outlined four strategic priorities to drive future success - reshaping the portfolio, delivering outstanding launches, simplifying the organization, and sustaining innovation in R&D.
- Sanofi entered exclusive negotiations with Boehringer Ingelheim for a potential business swap that would make Sanofi a global leader in consumer healthcare and Boehringer Ingelheim the second largest animal health company.
- Sanofi highlighted plans to focus resources on key therapeutic areas and launch several major new products, with an expectation of €12-
The biotechnology industry had an unprecedented year in 2014, reaching new highs in revenues, R&D spending, profits, financing amounts, and market capitalization. Strong product sales and approvals helped boost investor sentiment and company valuations. A surge in IPOs and follow-on financings provided the industry with historic levels of capital to fund innovation.
BMO Capital Markets 25th Global Metals & Mining Conference PresentationKinrossGold
Kinross Gold Corporation presented at the BMO Capital Markets Global Metals & Mining Conference on February 28 - March 2, 2016. Kinross delivered strong operational performance in 2015, meeting or exceeding its revised guidance targets. Kinross expects to produce 2.7-2.9 million ounces of gold equivalent in 2016 at an all-in sustaining cost of $890-990 per ounce and capital expenditures of $595 million. Kinross' diversified portfolio is expected to source over 60% of 2016 production from its Americas mines. Kinross outlined organic growth opportunities from its La Coipa project in Chile and exploration programs at Bald Mountain and across its global portfolio.
This document summarizes Kinross Gold Corporation's presentation at the CIBC Whistler Institutional Investor Conference in January 2016. Key points include: Kinross is focused on operational excellence, quality over quantity, disciplined capital allocation, and maintaining a strong balance sheet. For 2015, Kinross expects gold equivalent production of 2.5-2.6 million ounces at a production cost of sales of $690-730 per ounce and all-in sustaining costs of $975-1,025 per ounce, and capital expenditures of $650 million. Over 50% of Kinross' estimated 2015 production is from mines in the Americas.
Kinross Gold Corporation held a Q1 2016 results conference call and webcast on May 11, 2016. Key highlights from the call include: Kinross delivered strong performance in Q1 2016 with production increasing and costs decreasing year-over-year. Kinross is on track to meet its 2016 guidance targets. The Tasiast Phase One project is progressing well with engineering 55% complete and major earthworks scheduled to begin in June. Phase One is expected to significantly increase production and reduce costs at Tasiast.
Kinross Gold Corporation presented at the TD Securities 2016 Mining Conference in January 2016. The presentation focused on Kinross' principles of operational excellence, quality over quantity, disciplined capital allocation, and maintaining a strong balance sheet. It provided updates on Kinross' diversified portfolio of operating mines and organic growth opportunities, including positive pre-feasibility study results for the La Coipa Project and concepts for a phased expansion at Tasiast.
Kinross Gold Corporation completed studies on a two-phased expansion of its Tasiast mine in Mauritania. Phase One involves expanding the processing capacity to 12,000 tonnes per day at an initial capital cost of $300 million, which is expected to increase average annual production to 409,000 ounces, reduce costs per ounce by 50%, and generate an after-tax IRR of 20%. Phase Two pre-feasibility studies were also completed. The two-phased approach offers significant growth potential at a lower cost than previously estimated and allows flexibility to potentially proceed with a larger expansion in the future. Kinross is proceeding with Phase One of the expansion.
Kinross Gold Corp European Gold Forum PresentationKinrossGold
Kinross Gold Corporation is a gold mining company that produced 2.6 million ounces of gold equivalent in 2015, meeting or exceeding its revised guidance targets. For 2016, Kinross expects production of 2.7-2.9 million ounces at a cost of sales of $675-735 per ounce and all-in sustaining costs of $890-990 per ounce. Capital expenditures are forecasted to be $755 million. The Americas are expected to contribute 61% of 2016 production at a cost of sales of $730-790 per ounce from its six mines in the US, Brazil and Chile. Kinross has a diversified portfolio of operating mines and development projects globally.
Kinross Gold Corporation reported its fourth quarter and full-year 2015 results. Key highlights included meeting or exceeding its revised 2015 guidance by producing 2.6 million ounces of gold equivalent at a cost of sales of $696 per ounce and capital expenditures of $610 million. The company also acquired two producing mines in Nevada, enhancing its American portfolio. For 2016, Kinross expects to produce between 2.7-2.9 million ounces of gold equivalent at a reduced overhead expense of $165 million and capital expenditures of $595 million, excluding potential expansion at Tasiast.
062916 nevada mine tour presentation final printedKinrossGold
Kinross Gold Corporation hosted a mine tour at its Bald Mountain Mine in Nevada on June 29-30, 2016. The presentation provided an overview of Bald Mountain, including:
1) Bald Mountain is a large, open-pit heap leach gold mine in Nevada with significant mineral reserves and upside potential from resource conversion and exploration.
2) Near-term opportunities exist to potentially double mineral reserve estimates by the end of Q1 2017 through conversion of the Vantage Complex and Saga Extension.
3) Longer-term opportunities for further mine life extension include converting measured and indicated resources to reserves with additional drilling and permitting. Bald Mountain also has extensive exploration potential across its large land package.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos Corporation will be releasing an investor presentation for the third quarter of 2016. The presentation will provide investors with information on the company's financial performance and business operations for the recent quarterly period. Details on Glaukos' progress, strategies, and outlook will be shared in the upcoming Q3 2016 investor presentation.
ACQUISITION OF TWO QUALITY MINES IN NEVADAKinrossGold
Kinross has agreed to acquire two gold mines in Nevada from Barrick for $610 million in cash. This includes 100% ownership of the Bald Mountain mine and increasing its ownership in the Round Mountain mine to 50%. The acquisition enhances Kinross' portfolio by adding over 430,000 ounces of average annual gold production through 2018 and increasing reserves and resources. It provides upside potential from exploration at Bald Mountain and operational improvements at Round Mountain. The all-cash transaction maintains Kinross' strong balance sheet while increasing cash flow and lowering costs.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
Kinross Gold Corporation held a Q2 2016 results conference call on July 28, 2016. Key highlights included:
- Kinross generated $218 million in free cash flow in Q2 2016, increasing its cash balance to $968 million.
- Production was on track to meet 2016 guidance, with strong performances from mines in Russia, the US and Brazil.
- Operations at Tasiast were temporarily suspended in June due to work permit issues but are expected to resume in August.
- Kinross has attractive growth opportunities at its Bald Mountain and Round Mountain mines in Nevada.
- Kinross maintained a strong balance sheet and liquidity position of $2.5 billion to fund its projects.
Kinross Gold Corporation provides a presentation at the 2016 Denver Gold Forum discussing its operational excellence and outlook. Kinross forecasts 2016 gold equivalent production of 2.7-2.9 million ounces at a production cost of sales of $675-735 per ounce. Key growth opportunities include completing the Phase One expansion at Tasiast and further expanding production and reducing costs through a potential Phase Two project. Kinross also sees opportunities to increase reserves and extend mine life at Bald Mountain through conversion of resources and exploration.
SQM provides a notice stating that any forward-looking statements in the presentation involve risks and uncertainties that could cause actual results to differ from projections. The presentation then discusses SQM's overview, fertilizer and specialty chemical businesses, and financial information. It highlights SQM's global presence and leadership in key specialty products like lithium, iodine, and potassium nitrate. It also outlines growth opportunities through expansion projects and increasing demand for products.
This document discusses SQM's fertilizer business, focusing on its specialty plant nutrition segment. Specialty plant nutrition accounted for 28% of SQM's revenues and 22% of gross margin in the first 9 months of 2012. SQM has a 49% global market share for potassium nitrate and is the world's largest producer. It recently completed a new potassium nitrate facility that will help maintain its leading position.
SQM is a global producer of specialty plant nutrients, lithium and industrial chemicals. It has unique and abundant natural resources in Chile. It has a solid financial position with revenues of $1.8 billion, EBITDA of $758 million and a debt to equity ratio of 1.01. SQM has leading market positions in speciality fertilizers like potassium nitrate and industrial chemicals like solar salts. It is also the lowest cost producer of lithium and a major player in iodine.
SQM is a global producer of specialty plant nutrients, iodine, lithium, and industrial chemicals. In 2015, SQM reported revenues of $1.7 billion and EBITDA of $724 million, with a 42% EBITDA margin. SQM has unique and abundant natural resources in Chile, including the world's largest deposits of nitrates and iodine. It is also the lowest cost producer of lithium globally. SQM has a solid financial position and expects higher sales volumes and capital expenditures in 2016.
SQM is a global producer of specialty plant nutrients, lithium, iodine, and industrial chemicals. It has unique and abundant natural resources in Chile. SQM has leading market positions and is the lowest cost producer for several of its products. It has a solid financial position with stable revenues, earnings, and credit metrics. SQM continues to focus on cost savings programs and growing its specialty businesses.
The document discusses forward-looking statements made by SQM concerning its business outlook. It notes that while estimates are based on best judgment, actual results could differ materially from projections due to risks and uncertainties. It directs readers to SEC filings for further information on factors that could affect the accuracy of forward-looking statements.
The document discusses SQM's business outlook, noting that any statements about future economic performance or other financial forecasts constitute "forward-looking statements." It warns that a number of risks and uncertainties could cause actual results to differ from these statements. The document identifies public securities filings and other factors that should be considered regarding the accuracy of forward-looking information.
The document discusses SQM's business outlook, noting that any statements about future economic performance or other financial forecasts constitute "forward-looking statements." It warns that a number of risks and uncertainties could cause actual results to differ from these statements. The document identifies public securities filings and other factors that should be considered regarding the accuracy of forward-looking information.
This document discusses SQM's business outlook and provides forward-looking statements about financial performance. It notes that any forward-looking statements involve risks and uncertainties that could cause actual results to differ from expectations. It also states that the risks and uncertainties are identified in public filings with the SEC. Forward-looking statements should be considered in light of these risk factors.
SQM is a global producer of specialty plant nutrients, lithium and industrial chemicals. It has unique and abundant natural resources in Chile. SQM has leading market positions in several businesses including potassium nitrate, iodine, lithium and industrial chemicals. It has a solid financial position and expects higher sales volumes and prices in 2016 for key products like lithium and solar salts.
SQM is a global producer of specialty plant nutrients, lithium and industrial chemicals. It has unique and abundant natural resources in Chile. It has a solid financial position with revenues of $1.8 billion, EBITDA of $758 million and low debt levels. SQM holds leading market positions in speciality fertilizers like potassium nitrate and niche industrial chemicals like solar salts. It also has opportunities in lithium and metallic exploration.
SQM reported its 1Q2018 results. Revenue increased 11% to $519 million due to higher lithium and iodine prices outweighing lower sales volumes. Gross profit declined 22% to $517 million due to lower potassium sales and higher costs. The company is expanding lithium carbonate capacity to 180,000 MT by 2021 and lithium hydroxide capacity to 13,500 MT by 2018 through investments of $525 million from 2017-2021. SQM pays dividends according to a policy based on financial metrics and paid $114 million in interim dividends for 1Q2018.
SQM reported its 1Q2018 results. Revenue increased 11% to $519 million compared to 1Q2017, driven by higher prices for lithium and iodine which offset lower sales volumes. Gross profit decreased 4% to $178 million due to lower volumes. SQM expects continued growth in lithium demand and has expansion plans to increase lithium carbonate capacity to 180,000 MT by 2021. SQM pays dividends according to a policy based on financial metrics and paid $110 million, $100 million, and $114 million in dividends in 2018 related to 2017 and 2018 earnings.
SQM is a global producer of specialty plant nutrients, iodine, lithium, potassium chloride and industrial chemicals. It has unique and abundant natural resources in Chile which allow it to be the dominant or largest global producer in many of its business lines. It has a diversified customer base of thousands of customers in over 110 countries. SQM has maintained strong financial performance in recent years with consistent revenue growth, profitability, and low debt levels.
SQM presented its fourth quarter 2016 earnings, reporting revenues of $1.939 billion and EBITDA of $761 million, with strong contributions from lithium sales volumes and prices. The presentation outlined SQM's financial results and position, business segment highlights and outlook, capital expenditure plans, and considerations regarding arbitration with CORFO and market conditions. SQM aims to increase EBITDA to over $1 billion by 2020 through growth initiatives across its business segments.
The presentation summarizes SQM's financial results for the fourth quarter of 2016, including increased revenues driven by higher lithium sales volumes and prices, though lower prices in other businesses limited margins; it also outlines the company's growth strategy and capital expenditure plans to increase production of potassium nitrate, lithium, and solar salts through 2020.
SQM reported its third quarter 2017 results. The company saw higher revenues and gross profits compared to the third quarter of 2016, driven by increased volumes in iodine and industrial chemicals offsetting lower prices. Prices increased in lithium and potassium business lines. SQM expects continued demand growth for its lithium and specialty plant nutrients products. The company has several expansion projects planned between 2016-2022 to increase production capacities of various products, with over $1 billion in planned capital expenditures.
SQM reported its 2017 results. Key highlights included:
- Revenue of $2.2 billion and EBITDA of $894 million.
- Lithium sales volumes of 49.7k MT and revenues of $645 million, contributing 60% of gross profit.
- Iodine sales volumes of 12.7k MT and revenues of $252 million, contributing 7% of gross profit.
- Potassium nitrate sales volumes of 966.2k MT and revenues of $697 million, contributing 19% of gross profit.
- Planned expansions of lithium carbonate and hydroxide capacities in Chile by 2019.
- Capital expenditures framework of $517 million for 2018
This document provides an overview of SQM, a leading producer of specialty plant nutrients, iodine, lithium, potassium, and industrial chemicals. It discusses SQM's business segments and highlights, including its position as the world's lowest cost producer of lithium. It also outlines SQM's strategic goals, which include growing its lithium, solar salts, and specialty plant nutrients businesses. Additionally, the document summarizes SQM's capital expenditure plans and ongoing arbitration with CORFO regarding its lease agreement.
SQM reported its 2017 results. Key highlights included:
- Revenue of $2.2 billion and EBITDA of $894 million.
- Lithium sales volumes of 49.7k MT and revenues of $645 million, contributing 60% of gross profit.
- Iodine sales volumes of 12.7k MT and revenues of $252 million, contributing 7% of gross profit.
- Potassium nitrate sales volumes of 966.2k MT and revenues of $697 million, contributing 19% of gross profit.
- Planned expansions of lithium carbonate and hydroxide capacities in Chile by 2019.
SQM reported its 2017 results. Key highlights included:
- Revenue of $2.2 billion and EBITDA of $894 million.
- Lithium sales volumes of 49.7k MT and revenues of $645 million, contributing 60% of gross profit.
- Iodine sales volumes of 12.7k MT and revenues of $252 million, contributing 7% of gross profit.
- Potassium nitrate sales volumes of 966.2k MT and revenues of $697 million, contributing 19% of gross profit.
- Planned expansions of lithium carbonate and hydroxide capacities in Chile by 2019.
- Capital expenditures framework of $517 million for 2018
Zinc Sulfate Market Report | Global Forecast To 2028NikhilGhodse
This document provides a summary of a research report on the global zinc sulfate market. It discusses key segments of the market by type (zinc sulfate heptahydrate and zinc sulfate monohydrate) and application (agriculture, industry, food, and pharmacy). The report analyzes market size, growth rate, competitive landscape, trends, drivers, restraints and regional outlook for 15 major companies. It also describes the purpose of the study, methodology, and includes segmentation analysis, growth projections, and recommendations.
Europe Calcium Chloride Market by Product Type, Distribution Channel, End Use...IMARC Group
The Europe calcium chloride market size reached 716,000 Tons in 2022. Looking forward, IMARC Group expects the market to reach 804,600 Tons by 2028, exhibiting a growth rate (CAGR) of 1.83% during 2023-2028.
More Info:- https://www.imarcgroup.com/europe-calcium-chloride-market
"Global outlook for borates", presentation by Gary Goldberg, President & Chief Executive Officer, Rio Tinto Minerals, Industrial Minerals Congress, Miami, Florida, March 22 - 24, 2010
Chlorine Dioxide Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and ...IMARC Group
The global chlorine dioxide market size reached US$ 1,046.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,531.4 Million by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
More Info:- https://www.imarcgroup.com/chlorine-dioxide-market
SQM reported its 2Q2017 results. The company is a leading producer of lithium, iodine, potassium nitrate, and other specialty plant nutrients. In 1H2017, higher volumes of iodine and specialty plant nutrients outweighed lower prices, while lithium and potassium saw price increases. SQM has several expansion projects underway for lithium, iodine, and potassium production through 2018. It also has lithium projects in Argentina through a joint venture. SQM has a proven track record of generating cash and returning value to shareholders through dividends.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
2. Statements in this presentation concerning the Company’s business outlook or future
economic performances, anticipated profitability, revenues, expenses, or other
financial items, anticipated cost synergies and product or service line growth, together
with other statements that are not historical facts, are “forward-looking statements” as
that term is defined under Federal Securities Laws.
Any forward-looking statements are estimates, reflecting the best judgment of SQM
based on currently available information and involve a number of risks, uncertainties
and other factors that could cause actual results to differ materially from those stated
in such statements.
Risks, uncertainties, and factors that could affect the accuracy of such forward-looking
statements are identified in the public filing made with the Securities and Exchange
Commission, and forward-looking statements should be considered in light of those
factors.
2
Important Notice
3. Photo: Evaporation Ponds, Salar de Atacama
3
Investment Highlights
SQM at a Glance
Financial summary
2
1
3
Agenda
4. SQM at a Glance
World Leader in Specialty Businesses: Potassium Nitrate, Iodine,
lithium & Solar Salts
Global Company: Based in Santiago, Chile with sales in more than 115
countries and offices in 20 countries.
Financial Profile
Revenue 2013: US$ 2.2 Billion
EBITDA† 2013: US$ 833 Million
EBITDA Margin 2013: ~ 38%
Healthy Credit Metrics
Debt/Equity Ratio: .96
NFD/EBITDA 1.06
Current Ratio 3.40
Highest Liquidity in Chile
Listed on the Santiago Stock Exchange, and the NYSE since
1993 (Ticker: SQM)
Most liquid Chilean ADR on the NYSE in 2013
Financially Stable: Credit Ratings
Standard & Poors: BBB
Moodys: Baa1
Responsible Growth Within Core Business Lines
4Note: EBITDA: gross profit – SGA + depreciation & amortization
5. Fertilizers Specialty Chemicals
48% of world KNO3
market share1
Volumes2: 848k MT
Revenues3: 31% of
total (US$688mm)
Contribution to
Total Gross Profit4:
21%
Specialty Plant
Nutrients
Potassium
Strategically located
in South America
Volumes2: 1,435k
MT
Revenues3: 28% of
total (US$606mm)
Contribution to
Total Gross Profit4:
23%
Iodine &
Derivatives
Lithium &
Derivatives
Industrial
Chemicals
28% of world
market share1
Volumes2: 9.3k MT
Revenues3: 21% of
total (US$461mm)
Contribution to
Total Gross Profit4:
36%
27% of world
market share1
Volumes2: 36.1k MT
Revenues3: 9% of
total (US$197mm)
Contribution to
Total Gross Profit4:
13%
50% of world
industrial sodium
nitrate market share1
Volumes2: 176k MT
Revenues3: 7% of
total (US$154mm)
Contribution to Total
Gross Profit4: 6%
Note: 1Market share is measured by volume, and correspond to SQM estimates for 2013.
2 Volumes correspond to SQM volumes for 2013.
3 Revenues correspond to SQM revenues for 2013
4 Gross Profit corresponds to % of contribution to consolidated gross profit for 2013.
SQM at a Glance
5
6. Investment Highlights
Unique and Abundant Natural Resources1.
Sales in Diverse Industries, Sold Globally2.
SPN: Largest Global Producer3.
Industrial Chemicals: Dominant Player in a Niche Market7.
Potassium: Uniquely located to supply major markets4.
Lithium: Lowest-cost producer6.
Iodine: Leading player in strong market with diverse uses5.
Metallic Exploration: Exploration with low risk8.
Solid Financial Position and Financial Management9.
6
7. Caliche ore is only found
in Chile
The world’s largest
deposits of nitrate and
iodine
Low processing costs due
to its high concentrations
of potassium and lithium
Higher evaporation rates
7
Abundant natural resources enable long term planning
High-quality reserves, which allow low-cost and highly
productive operations
Caliche Ore
Salar Brines
Highlights
1. Unique and Abundant Natural Resources
8. 8
LatAm
30%
North Am.
25%
Europe
22%
Asia & Other regions
23%
Headquarters
SQM commercial office
Joint venture
Production facilities
Products are sold in more than 115 countries through our worldwide distribution network
Local presence in 20 countries to diversify operations, to satisfy local customers, and to access local raw materials
Products are used in diverse industries such as agriculture, human and animal nutrition, pharmaceutical, medical,
construction and electronics, among others, sold to diverse customers
2. Sales in Diverse Industries, Sold Globally
9. 9
SQM Highlights Potassium Nitrate
A world leader: 48% world market share1
Developed distribution network: Proximity to
customers allows us to meet changing needs and
new market tendencies.
Flexibility: Various soluble NPK plants worldwide
Diverse customer base: In 2013, SPN products sold
in over 90 countries
Prices for specialty fertilizers during 2013 were
approximately 6% less than prices seen in 2012
¹ Source: Company estimates. Tomato crop included in vegetable estimates
Potassium Nitrate: Industry Dynamics
41%
22%
28%
9%
1Source: Company estimates
Vegetables
Others
Industrial
Crops
Fruits
Niche market with specific benefits: Chlorine-free,
fully water soluble, and fast absorption.
Demand Drivers: Higher cost of land, water scarcity,
increased demand for higher quality crops
Demand growth in 2013: 2-3%1
Lower price elasticity relative to potassium chloride
3. SPN: Largest Global Producer
Main Uses: Premium Crops1
10. 0
400
800
1200
1600
2000
2006 2007 2008 2009 2010 2011 2012 2013
Th.MT
Year
10
SQM HighlightsPotassium Chloride: Industry Dynamics
9%
4. Potassium: Uniquely located to supply major markets
Potassium chloride is the most commonly used
potassium-based fertilizer. Sold all over the world
Growing Market: ~55-57 million metric tons in
20141
Strategically located in Southern Hemisphere
Growth expected in all major geographical
markets in 2014
Expansion of potassium-based products:
2014 effective capacity expected to be 2.3
million metric tons
Low-cost producer of KCL
Small player in total KCL market; price-taker
Flexibility to produce MOP, SOP, KNO3 depending
on market needs
SQM Production Volumes (MOP¹ and SOP²)
¹ Potassium chloride; ² Potassium sulfate
1Source: Company estimates for 2013
Potassium Chloride Demand 20131
LatAm 21%
China 20%
Europe 19%
North
America
16%
SE Asia 14%
India 6%
others 4%
11. 28%
28%
19%
17%
5%
3%
11
SQM Highlights
1Source: Company estimates
5. Iodine: Leading player in strong market
Iodine is mainly used in human & animal health
and nutrition. Major uses include X-ray contrast
media, LCD, pharmaceuticals and sanitizers
Global demand: CAGR of over 3% for the period
2003-20131
Global demand expected 2014: over 32,000 MT1
Limited cost-effective substitutes available
Limited sources of iodine worldwide
Industry Dynamics
Recycling
Others Chile
Others 3%
Japan
A world leader: 28% market share in 20131
Developed distribution and sales network: Can quickly
meet demands of market. Largest producer, reliable
supplier
Long-term relationship established with large customers
Current production capacity: 12,500 metric tons per year
Globally diversified customer base
Key Competitors1
USA
12. 27%
40%
19%
11%
SQM Highlights
6. Lithium: Lowest-Cost Producer
Industry dynamics
Global demand: CAGR of 7% for the 2003-2013
period.
Demand driver: batteries. Future potential related
to e-cars using lithium-ion batteries (LIB)
Other uses for lithium include lubricant, glass,
pharmaceuticals
Global lithium projects announced in China and
Canada
Leading chemical lithium producer in the world and the
lowest cost producer globally
Produce lithium carbonate, lithium hydroxide, and
lithium chloride.
Current lithium carbonate plant capacity stands at
48,000 metric tons per year
Average prices in the business line were approximately
12% higher in 2013 than average prices in 2012
China
Rockwood
Argentina
Others
Key Competitors
12
13. 13
SQM Highlights
7. Industrial Chemicals: Dominant Player in a Niche Market
Various traditional uses for industrial nitrates
related to detergents, glass, metal treatment, water
treatment, and explosives
Main products are three grades of sodium and
potassium nitrate for industrial applications
Solar Salts: New global demand for nitrates applied
to thermal energy storage.
50 MW → approximately 30,000 MT of solar
salts
Projects being developed globally
Industry dynamics
Operational flexibility with certain industrial sodium
and potassium nitrate products
Solar Salts:
Leading Producer with almost 70% market
shares
Volumes are expected to reach 70,000 MT in
2013 (sold 165,000 MT in 2012). SQM is
currently negotiating contracts for 2015
SQM produces both potassium nitrate and
sodium nitrate, the two raw materials in solar
salt production
Photo: Andasol Millenium Power Station, Spain
14. 14
SQM Finance Strategy
8. Solid financial Position and experienced management
Overview1
To be a strong and credible competitor
To be a strong credible supplier
Maintain and strengthen our leadership position in the
iodine, lithium, potassium nitrate and solar solar
businesses
Financial Policy establishes a maximum level of
consolidated leverage of 1.5x
High levels of liquidity and capital resources as of
December 2013
Cash, cash equivalents and time deposits
amounting to over US$900 million
Management team has average of 22+ years with
Company
Approximately US$5 billion in assets
Note: 1 Figures as of December 31, 2013
Photo: Evaporation Ponds, Salar de Atacama
15. 15
SQM at a Glance
Financial Summary
Investment Highlights
1
3
2
Photo: Port Facility, Tocopilla
Agenda
16. Potassium Nitrate Plant in Coya Sur (300,000
MT/year)
Increase Potassium production in the Salar de
Atacama to 2.3 million MT from 800,000 MT,
including the construction of MOP and granulated
MOP facilities in the Salar de Atacama
Increase Capacity of iodine to 12,500 MT
Various investments related to distribution and
infrastructure
Capital Expenditure Program
Capital Expenditures 2009 - 2013: US$2.0 Billion Capital Expenditure 2014: Approximately US$150
After intense investment during the past 5 years,
investment is expected to decrease in 2014
optimization of our muriate of potassium facility at
the Salar de Atacama;
various projects designed to maintain production
capacity, increased yields and reduce costs.
16
Photo: Evaporation ponds and silvinite stock pile, Salar de Atacama
Metallic Exploration
Between 2008 and 2013 SQM has invested
approximately US$40 million in metallic exploration,
and has identified over 50 areas of interest
Investment of over US$150 million expected over
the next 5-7 years
SQM has signed nine agreement with various third
parties, and we expect to sign agreements in 2014
18. Financial Performance
2 Net Financial Debt: interest bearing debt net of cash and cash equivalents,
considering the effects of derivatives
Note: 1 2009-2013 figures are based on IFRS numbers.
18
1,16
0,85 0,79 0,83
1,06
0
0,5
1
1,5
2
2,5
3
2009 2010 2011 2012 2013
Net Financial Debt / Adjusted EBITDA
41%
38%
45% 46%
38%
2009 2010 2011 2012 2013
EBITDARatio
Year
EBITDA/Revenues
19. Investment Highlights
Unique and Abundant Natural Resources1.
Sales in Diverse Industries, Sold Globally2.
SPN: Largest Global Producer3.
Industrial Chemicals: Dominant Player in a Niche Market7.
Potassium: Uniquely located to supply major markets4.
Lithium: Lowest-cost producer6.
Iodine: Leading player in strong market with diverse uses5.
Metallic Exploration: Exploration with low risk8.
Solid Financial Position and Financial Management9.
19
Contact Information:
Gerardo Illanes: VP of Finance and IR, gerardo.illanes@sqm.com
Kelly O’Brien: Head of Investor Relations, kelly.obrien@sqm.com